Tarsus Pharmaceuticals
Irvine
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $10K – $50K
- Total funding: $710.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: nasdaq:TARS
- Website: tarsusrx.com
- Phone: (949) 409-9820
Industries & Categories
Biopharma, Biotechnology, Life Science
Social Profiles
Canonical: https://fsome.com/organization/tarsus-pharmaceuticals-131065 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.